Abstract
The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Current Pharmaceutical Design
Title:The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Volume: 19 Issue: 40
Author(s): Katarzyna Regulska, Beata Stanisz and Milosz Regulski
Affiliation:
Keywords: The renin-angiotensin system, cancer therapy, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, transduction mechanisms.
Abstract: The role of the renin-angiotensin system (RAS) in the development of various malignancies has recently been extensively examined and, since it has been shown to significantly influence many aspect of cancer initiation and progression, the idea of RAS-targeted anticancer therapy has arisen. This article reviews the mechanisms underlying RAS-induced physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, inflammation, and protein degradation, emphasizing the associated cellular transduction schemes activated by main RAS effectors. Also the dual nature of RAS-dependent effects, resulting from its complex physiology has been commented. Finally, based on the available data from clinical trials and experimental studies, the possibilities of the introduction of RAS-modulating drugs into standard clinical practice in oncology have been discussed with the focus on both, positive and negative effects associated with the administration of various classes of pharmaceuticals to cancer patients.
Export Options
About this article
Cite this article as:
Regulska Katarzyna, Stanisz Beata and Regulski Milosz, The Renin-angiotensin System as a Target of Novel Anticancer Therapy, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/13816128113199990508
DOI https://dx.doi.org/10.2174/13816128113199990508 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Knockdown of H19 Enhances Differentiation Capacity to Epidermis of Parthenogenetic Embryonic Stem Cells
Current Molecular Medicine Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews Blood Infusion and the Risk of Haemorrhage in Patients Undergoing Cardiac Surgery with Extracorporeal Circulation
Current Vascular Pharmacology Fucose Specific Lectins in Cancer Research and Diagnosis
Drug Design Reviews - Online (Discontinued) Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Estimating Alzheimer’s Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia
Current Alzheimer Research Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature
Current Hypertension Reviews